MOTIV Bioresorbable Scaffold
Below-the-Knee Peripheral Artery Disease
Pre-market Approval (FDA Breakthrough)Active
Key Facts
Indication
Below-the-Knee Peripheral Artery Disease
Phase
Pre-market Approval (FDA Breakthrough)
Status
Active
Company
About REVA Medical
REVA Medical is a pioneer in bioresorbable polymer technology, having developed 19 polymer families over two decades. Its proprietary Tyrocore polymer platform underpins its commercial and pipeline products, including the CE-marked Fantom Encore coronary scaffold and the MOTIV BTK scaffold, which has FDA Breakthrough Designation. The company's strategy targets the large cardiovascular device market by offering temporary scaffolds that resorb, aiming to improve long-term patient outcomes compared to permanent metal implants. REVA operates as a commercial-stage entity in select European markets while advancing clinical programs for US market entry.
View full company profileTherapeutic Areas
Other Below-the-Knee Peripheral Artery Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Peripheral (BTK) Solution | Vantis Vascular | Development |
| Virtue® SAB | Orchestra BioMed | Investigational |